Cidara Therapeutics Says Partner Janssen Announced Its Intention To Discontinue Internal Development Of Majority Of Its Infectious Disease Pipeline
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics announced that its partner, Janssen, plans to discontinue the majority of its infectious disease pipeline. However, Janssen has not indicated any intention to terminate its agreement with Cidara. The two companies continue to collaborate on Phase 1 and Phase 2a clinical trials, with Janssen reimbursing Cidara for all ongoing development activities.
July 20, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite Janssen discontinuing most of its infectious disease pipeline, its collaboration with Cidara Therapeutics remains intact. This could potentially shield Cidara from immediate negative impacts.
Janssen's decision to discontinue most of its infectious disease pipeline could have been a major blow to Cidara. However, the fact that Janssen has not indicated any intention to terminate its agreement with Cidara and continues to reimburse it for ongoing development activities mitigates potential negative impacts.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Janssen, a subsidiary of Johnson & Johnson, is discontinuing most of its infectious disease pipeline. This could potentially lead to cost savings but also indicates a shift in strategic focus.
The discontinuation of most of Janssen's infectious disease pipeline could lead to cost savings in the short term. However, it also indicates a shift in strategic focus, which could have longer-term implications for Johnson & Johnson's business.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100